Weiss Ratings Reaffirms Sell (D-) Rating for Anebulo Pharmaceuticals (NASDAQ:ANEB)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Anebulo Pharmaceuticals (NASDAQ:ANEB), suggesting skepticism about the company's stock performance.
• Simultaneously, Maxim Group downgraded the stock from a "strong-buy" to a "hold" rating, with analysts currently showing a consensus rating of "Hold" and an average price target of $5.50.
• Anebulo Pharmaceuticals' stock is currently trading at $2.30, with a recent decrease of 0.4% and a market cap of approximately $94.48 million.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Maxim Group cut shares of Anebulo Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 23rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $5.50.

Anebulo Pharmaceuticals Stock Down 0.4%

ANEB stock traded down $0.01 during trading on Wednesday, hitting $2.30. The company had a trading volume of 14,981 shares, compared to its average volume of 155,794. The firm has a 50-day moving average price of $2.47 and a 200-day moving average price of $1.75. The stock has a market cap of $94.48 million, a price-to-earnings ratio of -8.85 and a beta of -0.89. Anebulo Pharmaceuticals has a 12 month low of $0.80 and a 12 month high of $3.42.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) last announced its quarterly earnings data on Monday, September 29th. The company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). Equities analysts expect that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 47,954 shares of the company's stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 28.40% of the company's stock.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.